Farmacoriflessioni
L’uso dei farmaci oftalmologici nella popolazione pediatrica in italia
TOPICAL OCULAR DRUGS IN THE ITALIAN PAEDIATRIC POPULATION
F. Fortinguerra, A. Clavenna, M. Bonati
Maggio 2011 - pagg. 311 -318
Abstract
Aim: A study was planned to analyse the availability and the licensing status of ocular drugs
marketed in Italy and evaluate the evidence on their safety and efficacy in paediatric population.
Materials and methods: A quantitative analysis was performed in order to evaluate the number of ocular drugs with a paediatric licence in Italy. A literature search was also performed in MEDLINE and EMBASE for randomized controlled trials (RCTs) concerning ophthalmic pharmacological therapy in children aged < 18 years, published up to October 2010. A search in the international clinical trial registries and in the list of paediatric investigation plans (PIPs) approved by EMA was performed in order to find which ocular drugs are under paediatric investigation.
Results: In all, of 195 ocular drugs identified, 130 (67%) of which were marketed in Italy, 62 (48%) with a paediatric licence. No published RCTs were found for one third of ocular drugs licensed for paediatric use in Italy, while 21% of all retrieved studies were related to 23 drugs not licensed for paediatric use. 59 (46%) of 128 retrieved RCTs regarded mydriatic/cycloplegic medications. 62 RCTs (56% completed) on 46 drugs, were found in the international clinical trial registries, while only 3 PIPs were approved by EMA. Cyclosporine and bevacizumab were the drugs involved in many ongoing studies.
Conclusions:There is a need for further research and clinical development in the paediatric ophthalmic area, where the availability of effective and up-to-date treatments investigated in children remains a priority.
Materials and methods: A quantitative analysis was performed in order to evaluate the number of ocular drugs with a paediatric licence in Italy. A literature search was also performed in MEDLINE and EMBASE for randomized controlled trials (RCTs) concerning ophthalmic pharmacological therapy in children aged < 18 years, published up to October 2010. A search in the international clinical trial registries and in the list of paediatric investigation plans (PIPs) approved by EMA was performed in order to find which ocular drugs are under paediatric investigation.
Results: In all, of 195 ocular drugs identified, 130 (67%) of which were marketed in Italy, 62 (48%) with a paediatric licence. No published RCTs were found for one third of ocular drugs licensed for paediatric use in Italy, while 21% of all retrieved studies were related to 23 drugs not licensed for paediatric use. 59 (46%) of 128 retrieved RCTs regarded mydriatic/cycloplegic medications. 62 RCTs (56% completed) on 46 drugs, were found in the international clinical trial registries, while only 3 PIPs were approved by EMA. Cyclosporine and bevacizumab were the drugs involved in many ongoing studies.
Conclusions:There is a need for further research and clinical development in the paediatric ophthalmic area, where the availability of effective and up-to-date treatments investigated in children remains a priority.
Parole chiave
Classificazione MeSH
Bibliografia
1. Roarty JD. Ophth almologic drugs in infants and children. In: Yaffe SJ, Aranda JV (Eds.). Neonatal and Pediatric Pharmacology, 3rd ed. Philadelphia, PA: Lippincott Williams&Wilkins, 2005:340-8. 2.Wallace DK, Steinkuller PG. Ocular medications in children. Clin Pediatr 1998;37:645-52.
3. Chung I, Buhr V. Topical ophthalmic drugs and the pediatric patient. Optometry 2000;71: 511-8.
4. Coulter RA. Pediatric use of topical ophthalmic drugs. Optometry 2004;75:419-9.
5. Levy Y, Zadok D. Systemic side effects of ophthalmic drops. Clin Pediatr (Phila) 2004; 43:99-101.
6. Metry DW, Hebert AA. Topical therapies and medications in the paediatric patient. Pediatr Clin North Am 2000;47:867-76.
7. Alpay A, Ermis B, Ugurbas SC, Battal F, Sagdik HM. The local vasoconstriction of infant’s skin following instillation of mydriatic eye drops. Eur J Clin Pharmacol 2010;66:1161-4. 8.Martinez SV, Junceda MC. Systemic adverse reactions to topical ocular medications in children: A call for attention. Acta Pediatrica Espanola 2005;63:121-2.
9. Coppens G, Stalmans I, Zeyen T, Casteels I. The safety and efficacy of glaucoma medication in the paediatric population. J Pediatr Ophthalmol Strabismus 2009;46:12-8.
10. AIFA. Segnalazioni di reazioni avverse al collirio a base di tropicamide e fenilefrina. Raccomandazioni del gruppo di lavoro sui farmaci pediatrici dell’AIFA. http://www. agenziafarmaco. it/it/content/segnalazioni-di-reazioni- avverse-al-collirio-base-di-tropicamide-e-fenilefrina (accesso del 20 dicembre 2010). 11.World Health Organization (WHO). Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/(accesso del 20 dicembre 2010).
12. MASSON. Banche dati del farmaco. http://www.codifa.it/(S(dykvoo55dg1wsr3 hynkcbg55))/Ricerca.aspx (accesso del 20 dicembre 2010). 13.WHO. The International Clinical Trials Registry Platform. ICTRP; http://www.who.int/ trialsearch (accesso del 20 dicembre 2010).
14. US National Institutes of Health. Clinical- Trials.gov registry: http://clinicaltrials.gov/ ct2/search. (accesso del 20 dicembre 2010).
15. International Standard Randomised Controlled Trial Number Register, ISRCTN. http://www.controlled-trials.com/isrctn/ (accesso del 20 dicembre 2010).
16. European Medicines Agency (EMA). Opinions and Decisions on Paediatric Investigation Plans (PIPs). http://www.emea.europa. eu/htms/human/paediatrics/decisions.htm (accesso del 20 dicembre 2010).
17. The Royal College of Ophthalmologists. Guidelines for the Management of Strabismns in Childhood. July 2006. http://www.rcophth. ac.uk/page.asp?section=493&search= (accesso del 20 dicembre 2010).
18. European Medicines Agency (EMA). Revised priority list for studies into off-patent paediatric medicinal products for the Fifth Call 2010 of the 7th Framework Programme of the European Commission. http://www. ema.europa.eu/docs/en_GB/document_libra ry/Other/2009/10/WC500004017.pdf (accesso del 20 dicembre 2010).
19. Cincinnati Children’s Hospital Medical Center. Best evidence statement (BESt). Treatment of amblyopia in children. Cincinnati (OH): Cincinnati Children’s Hospital Medical Center; 2007; 5 p. http://www. guideline. gov/content.aspx?id=14288 (accesso del 20 dicembre 2010).
20. Taylor RH. The Royal College of Ophthalmologists. Guidelines for the Management of Strabismns in Childhood. June 2007 Author Review Date 2009. http://www.rcophth. ac.uk/docs/publications/paed-patient-information/ Strabismus.pdf (accesso del 20 dicembre 2010).
21. Moore W, Nischal KK. Pharmacologic management of glaucoma in childhood. Paediatr Drugs 2007;9:71-9.
22. University of Texas, School of Nursing, Family Nurse Practitioner Program. Guidelines for the treatment and management of acute bacterial conjunctivitis in children and adults. Austin (TX): University of Texas, School of Nursing; 2005. http://www.guidelines. gov/ content.aspx?id=7353 (accesso del 20 dicembre 2010).
23. Zin A, Florêncio T, Fortes Filho JB, et al. Brazilian guidelines proposal for screening and treatment of retinopathy of prematurity (ROP). Arq Bras Oftalmol 2007;70:875-83.
24. Recommendations for prevention of neonatal ophthalmia. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. Can Med Assoc J 1983;129:554-5.
25. Gray C. Systemic toxicity with topical ophthalmic medications in Children. Paed Perinat Drug Ther 2006;7:23-9.
26. Nonobe NI, Kachi S, Kondo M, et al. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Retina 2009;29:579-85.
27. British National Formulary for Children. British National Formulary 2010-2011. http://bnfc.org/bnfc/index.htm(accesso del 20 dicembre 2010).
28. Sassa Y, Hata Y. Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor. Clin Ophthalmol 2010;4:275-83.
29. Mantagos IS, VanderveenDK, Smith LEH. Emerging Treatments for Retinopathy of Prematurity. Seminars in Ophthalmology 2009;24: 82-6.
30. Lin KL, Hirose T, Kroll AJ, Lou PL, Ryan EA. Prospects for treatment of pediatric vitreoretinal diseases with vascular endothelial growth factor inhibition. Seminars in Ophthalmology 2009;24:70-6.
31. Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008;92:1450-5.
32. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008;28:S19-25.
33. Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008;28:S13-8.
34. Labetoulle M, Frau E, Le Jeunne C. Systemic adverse effects of topical ocular treatments. Presse Med 2005;34:589-95.
35. Hoppu K. Paediatric clinical pharmacology at the beginning of a new era. Eur J Clin Pharmacol 2008;64:201-5.
36. Macrae D. Conducting clinical trials in pediatrics. Crit Care Med 2009;37(1 Suppl):S136-9.
37. Sheldrick JH, Wilson AD, Vernon SA, Sheldrick CM. Management of ophthalmic disease in general practice. Br J Gen Pract 1993;43: 459-62.
38. Jefferys DB, Jones KH. EMEA and the new pharmaceutical procedures for Europe. Eur J Clin Pharmacol 1995;47:471-6.
39. Pandolfini C, Bonati M. European paediatric research and children’s therapeutic needs. Acta Paediatr 2008;97:1232-7.
40. Choonara I. Regulation of drugs for children in Europe. BMJ 2007;335:1221-2. 41.Hoppu K. Can we get the necessary clinical trials in children and avoid the unnecessary ones? Eur J Clin Pharmacol 2009;65:747-8.
42. Abraham J. Making regulation responsive to commercial interests: streamlining drug industry watchdogs. BMJ 2002;325:1164-9.
43. Bonati M, Pandolfini C. Is it time for a European formulary of paediatric medicines? Arch Dis Child 2004;89:890-1.
Corrispondenza: filomena.fortinguerra@marionegri.it